[HTML][HTML] GRPR-targeting radiotheranostics for breast cancer management
A D'Onofrio, S Engelbrecht, T Läppchen… - Frontiers in …, 2023 - frontiersin.org
Breast Cancer (BC) is the most common cancer worldwide and, despite the advancements
made toward early diagnosis and novel treatments, there is an urgent need to reduce its …
made toward early diagnosis and novel treatments, there is an urgent need to reduce its …
[HTML][HTML] Joint EANM-SNMMI guideline on the role of 2-[18F] FDG PET/CT in no special type breast cancer
SC Vaz, JPP Woll, F Cardoso, D Groheux… - European Journal of …, 2024 - Springer
Purpose To provide an organized, international, state-of-the-art, and multidisciplinary
guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and …
guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and …
Women's Health Update: Growing Role of PET for Patients with Breast Cancer
GA Ulaner, SC Vaz - Seminars in Nuclear Medicine, 2024 - Elsevier
Positron Emission Tomography (PET) has been growing in usage for patients with breast
cancer, due to an increased number of FDA-approved PET radiotracers pertinent to patients …
cancer, due to an increased number of FDA-approved PET radiotracers pertinent to patients …
[HTML][HTML] The Pattern of Metastatic Breast Cancer: A Prospective Head-to-Head Comparison of [18F]FDG-PET/CT and CE-CT
R Gram-Nielsen, IY Christensen, M Naghavi-Behzad… - Journal of …, 2023 - mdpi.com
The study aimed to compare the metastatic pattern of breast cancer and the intermodality
proportion of agreement between [18F] FDG-PET/CT and CE-CT. Women with metastatic …
proportion of agreement between [18F] FDG-PET/CT and CE-CT. Women with metastatic …
Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with Breast Cancer
GA Ulaner, SC Vaz, D Groheux - PET clinics, 2024 - pet.theclinics.com
A quarter century ago, breast cancer was predominantly evaluated by morphology.
However, with the advancement of molecular technologies, breast cancer is now better …
However, with the advancement of molecular technologies, breast cancer is now better …
[HTML][HTML] Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic …
J Boers, B Eisses, MC Zwager, JJL van Geel, F Bensch… - Diagnostics, 2024 - mdpi.com
Background: In metastatic breast cancer (MBC),[18F] fluorodeoxyglucose positron emission
tomography/computed tomography ([18F] FDG-PET/CT) can be used for staging. We …
tomography/computed tomography ([18F] FDG-PET/CT) can be used for staging. We …
Joint EANM-SNMMI guideline on the role of 2-[¹⁸F] FDG PET/CT in no special type breast cancer (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)
SC Vaz, JPP Woll, F Cardoso… - … journal of nuclear …, 2024 - repository.uantwerpen.be
Introduction There is much literature about the role of 2-[F-18] FDG PET/CT in patients with
breast cancer (BC). However, there exists no international guideline with involvement of the …
breast cancer (BC). However, there exists no international guideline with involvement of the …
[HTML][HTML] Monitoring treatment response in metastatic breast cancer: impact of FDG-PET/CT on survival and costs
M Naghavi-Behzad - 2023 - portal.findresearcher.sdu.dk
Background: Various diagnostic modalities are being used for staging metastatic disease in
breast cancer patients since international guidelines do not yet provide clear …
breast cancer patients since international guidelines do not yet provide clear …